BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BTXA-51’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BTXA-51 overview
BTXA-51 is under development for the treatment of relapsed or refractory acute myeloid leukemia, high risk myelodysplastic syndrome, metastatic solid tumor, estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) metastatic breast cancer and liposarcoma. It is administered by oral route. The drug candidate is a multi-kinase inhibitor that acts by targeting casein kinase I alpha (CKI-alpha) as well as super enhancer targets (CDK7/CDK9).
It was also under development for the treatment of B-cell non-Hodgkin lymphoma
Edgewood Oncology overview
Edgewood Oncology offers healthcare services including cancer, hematology, oncology and medical care services. The company is headquartered in New Castle, Delaware, the US.
For a complete picture of BTXA-51’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
